This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Malone, R. S.
Right arrow Articles by Teitelbaum, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malone, R. S.
Right arrow Articles by Teitelbaum, I.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2001, p. 2949-2954, Vol. 45, No. 10
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.10.2949-2954.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Pharmacokinetics of Levofloxacin and Ciprofloxacin during Continuous Renal Replacement Therapy in Critically Ill Patients

Rebecca S. Malone,1 Douglas N. Fish,2,3,* Edward Abraham,3 and Isaac Teitelbaum4

Department of Pharmacy Practice and Science, University of Arizona Health Sciences Center, Tucson, Arizona,1 and Department of Pharmacy Practice,2 Division of Pulmonary Sciences and Critical Care Medicine,3 and Division of Renal Diseases and Hypertension,4 University of Colorado Health Sciences Center, Denver, Colorado

Received 4 December 2000/Returned for modification 27 March 2001/Accepted 10 July 2001

The pharmacokinetics of intravenously administered levofloxacin and ciprofloxacin were studied in intensive care unit patients during continuous venovenous hemofiltration (CVVH; four patients received levofloxacin, and five received ciprofloxacin) or hemodiafiltration (CVVHDF; six patients received levofloxacin, and five received ciprofloxacin). Levofloxacin clearance was substantially increased during both CVVH and CVVHDF, while ciprofloxacin clearance was affected less. The results of this study suggest that doses of levofloxacin of 250 mg/day and ciprofloxacin of 400 mg/day are sufficient to maintain effective drug concentrations in the plasma of patients undergoing CVVH or CVVHDF.

* Corresponding author. Mailing address: University of Colorado Health Sciences Center, Department of Pharmacy Practice, School of Pharmacy, Campus Box C-238, 4200 East Ninth Ave., Denver, CO 80262. Phone: (303) 315-5136. Fax: (303) 315-4630. E-mail: doug.fish{at}uchsc.edu.

Antimicrobial Agents and Chemotherapy, October 2001, p. 2949-2954, Vol. 45, No. 10
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.10.2949-2954.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Li, A. M. M. Y., Gomersall, C. D., Choi, G., Tian, Q., Joynt, G. M., Lipman, J. (2009). A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data?. J Antimicrob Chemother 64: 929-937 [Abstract] [Full Text]  
  • Fish, D. N., Teitelbaum, I., Abraham, E. (2005). Pharmacokinetics and Pharmacodynamics of Imipenem during Continuous Renal Replacement Therapy in Critically Ill Patients. Antimicrob. Agents Chemother. 49: 2421-2428 [Abstract] [Full Text]  
  • Fuhrmann, V., Schenk, P., Jaeger, W., Ahmed, S., Thalhammer, F. (2004). Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. J Antimicrob Chemother 54: 780-784 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»